OPPM
SUPN icon

Opus Point Partners Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Opus Point Partners Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,648
Closed -$408K – 71
2019
Q1 		$408K Buy
+11,648
New +$433K 0.55% 46

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Opus Point Partners Management's SUPN Position: Q2 2019 in Review

Opus Point Partners Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 11,648 shares — an estimated $408K sold.

Opus Point Partners Management first reported a position in SUPN in Q1 2019 and held it in 1 quarter. The position peaked at $408K in Q1 2019. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

  • Opus Point Partners Management reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 11,648 Supernus Pharmaceuticals shares in Q2 2019, an estimated $408K.
  • Opus Point Partners Management first reported a position in Supernus Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Opus Point Partners Management's Supernus Pharmaceuticals position peaked at $408K in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.